Talampanel

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Talampanel 是一种口服选择性 α-氨基-3-羟基-5-甲基-4-异恶唑丙酸酯受体拮抗剂，具有抗癫痫活性。

Talampanel is an orally and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist with anti-seizure activity. Talampanel (IVAX) has neuroprotective effects in rodent stroke models.(In Vivo):Talampanel (p.o.; 5 mg/kg; once a day; 2 weeks) decreases motoneuronal calcium in a mouse model of ALS .

——

Talampanel (orally administration; 5 mg/kg; once a day; 2 weeks) reduces motoneuronal calcium in a mouse model of ALS, but its efficacy declines as the disease progresses. Animal Model:Female mutant SOD1 Tg mice Dosage:5 mg/kg Administration:Orally administration; 5 mg/kg; once a day; 2 weeks Result:Had a significant effect in reducing the calcium level only at the age of 12 weeks.

GYKI-53773 | LY-300164

Apoptosis

Apoptosis

ASK1

——

——

161832-65-1

337.379

C19H19N3O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (296.41 mM)

C[C@@H]1Cc2cc3OCOc3cc2C(=NN1C(C)=O)c1ccc(N)cc1

——

(-20℃)

With Ice Pack

≥ 2 years